Jeffrey Marshall
Pulmonary Disease · Glen Burnie, MDNPI 1780978114
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Inari Medical, Inc. at 37.7% of the total. Reporting peaked in 2023 at $1,838 and has fallen 94.1% since, to $108 in 2025.
Across 72 payments — averaging $68.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$2K
- Veran Medical Technologies, Inc.$1K
- Actelion Pharmaceuticals US, Inc.$322
- GSK$254
- Cardiovascular Systems Inc.$188
- Vero Biotech Inc.$159
- plus $658 from 14 others
Across 8 payments — averaging $3141.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$14K
- Surmodics, Inc.$11K
What the payments were for
- Travel & lodging$2,44650%
- Food & beverage$2,32547%
- Education$1683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 16 | $1,863 |
| Veran Medical Technologies, Inc. | 6 | $1,496 |
| Actelion Pharmaceuticals US, Inc. | 9 | $322 |
| GSK | 12 | $254 |
| Cardiovascular Systems Inc. | 1 | $188 |
| Vero Biotech Inc. | 1 | $159 |
| Regeneron Healthcare Solutions, Inc. | 6 | $146 |
| Grifols USA, LLC | 5 | $108 |
| United Therapeutics Corporation | 3 | $79 |
| AstraZeneca | 2 | $44 |
| Intuitive Surgical | 2 | $41 |
| Pulmonx Corporation | 1 | $41 |
| Harmony Biosciences LLC | 1 | $37 |
| Boehringer Ingelheim | 1 | $30 |
| Ambu Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Pfizer | 1 | $21 |
| Insmed, Inc. | 1 | $18 |
| Resmed Corp | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,939 in reported general payments places this provider in the 70th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 17 | $250,582 |
| Orenitram ErTreprostinil Diolamine | 11 | $74,864 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $36,450 |
| EliquisApixaban | 23 | $19,315 |
| Spiriva RespimatTiotropium Bromide | 21 | $14,273 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $12,257 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,930 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $7,761 |
| JardianceEmpagliflozin | 12 | $7,744 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $916 |
| Azithromycin | 15 | $700 |
| Roflumilast | 11 | $575 |
| Potassium Chloride | 26 | $260 |
| Furosemide | 47 | $213 |
| Nifedipine ErNifedipine | 12 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $254 | $44,38058 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Jardiance | $30 | $34,27453 claims |
| PfizerEliquis | $21 | $19,31523 claims |
| AstraZenecaBreztri Aerosphere | $44 | $7,76115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Glen Burnie
- Peter OlivieriGlen Burnie$9K
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- da Wei LiaoBethesda$310K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.